VivoSeq
Oncology

Neuroendocrine Neoplasm

51

Pipeline Programs↗

11

Active Trials↗

28

Companies Involved↗

Neuroendocrine Neoplasm is a moderately active landscape with 51 programs across 28 companies. The most active players are Merck & Co., Avyxa, Compass Therapeutics. 18 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

19/100

Mech. Concentration

6/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

3 programs

Phase 2A

Avyxa

2 programs

Phase 2C

Compass Therapeutics

1 program

Phase 2S

Syndax Pharmaceuticals

1 program

Phase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

1 program

Phase 2V

Vion Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

37 of 49 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody816%Peptide36%Radiopharmaceutical12%

Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 100% of 51 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed6 · 30%
Recruiting5 · 25%
Active, not recruiting3 · 15%
Unknown status3 · 15%
Not yet recruiting3 · 15%

Clinical Trials

Trial Activity

20 trials

Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT07272512·350 enrolled
Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
Recruiting·EEuropean Institute of Oncology·Phase 2·NCT05554003·46 enrolled
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Recruiting·WWashington University School of Medicine·Phase 2·NCT06926634·32 enrolled
Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT06788938·29 enrolled
NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07077551·28 enrolled
Cabozantinib in High Grade Neuroendocrine Neoplasms
Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04412629·35 enrolled
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Active, not recruiting·SSinotau Pharmaceutical Group·Phase 2/3·NCT06398444·74 enrolled
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm
Active, not recruiting·BBiotheus Inc.·Phase 2·NCT05879055·31 enrolled
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
Not yet recruiting·FFudan University·Phase 2·NCT05316480·42 enrolled
The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07077564·35 enrolled
A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors
Not yet recruiting·CCompass Therapeutics·Phase 2·NCT07684170·58 enrolled
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Completed·—·Phase 2·NCT01237457·143 enrolled
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT03453489·4 enrolled
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Completed·Novartis logoNovartis·Phase 3·NCT06240741·71 enrolled
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT03095274·126 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)